EGFR and lung adenocarcinoma: In the WJOG8114LTR multicenter, single-arm, prospective phase II study, the clinical significance of monitoring cfDNA was evaluated in 57 EGFR mutated, advanced lung adenocarcinoma patients during treatment with afatinib, an irreversible EGFR inhibitor.